Due to the overexpression of S100A16 in PDAC and its role in promoting cancer progression through FGF19-mediated signaling pathways, S100A16, as well as the potentially involved FGF19 signaling pathways, are considered promising therapeutic targets for PDAC. Here, S100A16 is linked to cancer.